Will AHA Trial Data Change Mineralys Therapeutics (MLYS) NarrativeSimplywall·Oct 4, 2026 at 07:16 AMMLYS-0.38%
Mineralys Therapeutics CEO Jon Congleton disposes of $1,909,665 common sharesPUBT·Oct 2, 2026 at 09:54 PMMLYS-0.38%
Mineralys Therapeutics Announces Presentation of New Lorundrostat Data at the American Society of Nephrology (ASN) Kidney Week 2026 | MLYS Stock NewsStockTitan·Oct 2, 2026 at 12:30 PMMLYS-0.38%
Mineralys Therapeutics Announces Presentation of Lorundrostat Data at American Heart Association Hypertension Scientific Sessions 2026Unusual Whales·Oct 1, 2026 at 08:07 PMMLYS-0.38%
Mineralys to present lorundrostat Explore-OSA hypertension trial data at AHA Hypertension Scientific Sessions 2026PUBT·Oct 1, 2026 at 08:06 PMMLYS-0.38%
Mineralys Therapeutics (NASDAQ:MLYS) Stock Falls 6.1% - What's Next?Market Beat·Oct 1, 2026 at 07:22 PMMLYS-0.38%
BPCR: Share price up, net income per share slightly down; portfolio diversified with new loans and full recovery from defaultQuartr·Sep 25, 2026 at 02:37 PMESPR0.00%MLYS-0.38%
Mineralys director Brian Taylor Slingsby disposes of 104,320 common shares for $3 millionPUBT·Sep 25, 2026 at 01:50 AMMLYS-0.38%
Mineralys Therapeutics joins Stifel Virtual Cardiometabolic Forum fireside chatPUBT·Sep 24, 2026 at 08:05 PMSF-0.09%MLYS-0.38%
Mineralys says Transform-HTN extension data on lorundrostat set for late-breaking AHA 2026 presentationPUBT·Sep 23, 2026 at 08:06 PMMLYS-0.38%
